[1] WHO Coronavirus(COVID-19) Dashboard[EB/OL]. [2023-04-23]. https://covid19.who.int/.
[2] KOELLE K,MARTIN M A,ANTIA R,et al. The changing epidemiology of SARS-CoV-2[J]. Science,2022,375(6585):1116-1121.
[3] LONG B,CARIUS B M,CHAVEZ S,et al. Clinical update on COVID-19 for the emergency clinician:presentation and evaluation[J]. Am J Emerg Med,2022,54:46-57.
[4] LE TTB,VASANTHAKUMARAN T,THI H H,et al. SARS-CoV-2 Omicron and its current known unknowns:a narrative review[J]. Rev Med Virol,2023,33(1):e2398.
[5] CHOW E J,UYEKI T M,CHU H Y. The effects of the COVID-19 pandemic on community respiratory virus activity[J]. Nat Rev Micr-obiol,2023,21(3):195-210.
[6] 中国国家流感中心流感周报[EB/OL]. [2023-04-23]. https://ivdc.chinacdc.cn/cnic/zyzx/lgzb/.
[7] UYEKI T M,HUI D S,ZAMBON M,et al. Influenza[J]. Lancet,2022, 400(10353):693-706.
[8] OSMAN M,KLOPFENSTEIN T,BELFEKI N,et al. A comparative systematic review of COVID-19 and influenza[J]. Viruses,2021,13 (3):452.
[9] ZHANG J,HUANG X,TAO Z. Correlation of clinical characteristics between patients with seasonal influenza and patients infected by the wild type or delta variant of SARS-CoV-2[J]. Front Public Health,2022,10:981233.
[10] 中华人民共和国国家卫生健康委员会办公厅,中华人民共和国国家中医药管理局综合司. 新型冠状病毒感染诊疗方案(试行第十版)[J]. 中国医药,2023,18(2):161-166.
[11] 国家卫生健康委办公厅,国家中医药管理局办公室. 流行性感冒诊疗方案(2020年版)[J]. 中国病毒病杂志,2021,11(1):1-5.
[12] TAN J,LIANG L,HUANG P,et al. Changes in influenza activities impacted by NPI based on 4-year surveillance in China:epidemic patterns and trends[J]. J Epidemiol Glob Health,2023,13(3):539-546.
[13] 李姗姗,李艳宇,孙冰洁,等. 2017—2019年北京市东城区流感流行病学特征分析[J]. 中国生物制品学杂志,2022,35(7):836-839.
[14] YANG W,YANG S,WANG L,et al. Clinical characteristics of 310 SARS-CoV-2 Omicron variant patients and comparison with Delta and Beta variant patients in China[J]. Virol Sin,2022,37(5):704-715.
[15] CUI A,XIE Z,XU J,et al. Comparative analysis of the clinical and epidemiological characteristics of human influenza virus versus human respiratory syncytial virus versus human metapneumovirus infection in nine provinces of China during 2009-2021[J]. J Med Virol,2022,94(12):5894-5903.
[16] 杨芝芝,杨洁,邓建军,等. 血常规指标及比值变化在新型冠状病毒肺炎和流感患者鉴别诊断中的价值研究[J]. 国际医药卫生导报,2022,28(20):2876-2880.
[17] NARDO A D,SCHNEEWEISS-GLEIXNER M,BAKAIL M,et al. Pathophysiological mechanisms of liver injury in COVID-19[J]. Liver Int,2021,41(1):20-32.
[18] SHAFRAN N,ISSACHAR A,SHOCHAT T,et al. Abnormal liver tests in patients with SARS-CoV-2 or influenza-prognostic similarities and temporal disparities[J]. JHEP Rep,2021,3(3):100258.
[19] ALEEM A,SHAH H. Gastrointestinal and hepatic manifestations of coronavirus(COVID-19)[M]. 2nd ed. Treasure Island(FL):StatPearls Publishing,2023:196-209.
[20] BLOOM P P,MEYEROWITZ E A,REINUS Z,et al. Liver biochemistries in hospitalized patients with COVID-19[J]. Hepatology,2021,73(3):890-900.
[21] WANG S,MA P,ZHANG S,et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes:a multi-centre retrospective study[J]. Diabetologia,2020,63(10):2102-2111.
[22] LU J Y,WILSON J,HOU W,et al. Incidence of new-onset in-hospital and persistent diabetes in COVID-19 patients: comparison with influenza[J]. E Bio Medicine,2023,90:104487.
[23] KHUNTI K,DEL P S,MATHIEU C,et al. COVID-19,hyperglycemia,and new-onset diabetes[J]. Diabetes Care,2021,44(12):2645-2655.
[24] BATTAGLINI D,LOPES-PACHECO M,CASTRO-FARIA-NETO H C,et al. Laboratory biomarkers for diagnosis and prognosis in COVID-19[J]. Front Immunol,2022,13:857573.
[1]冯雪,李伯君,赵芳,等.新型冠状病毒肺炎重症患者高氧血症的危害及精准氧气治疗[J].天津医科大学学报,2021,27(04):423.
[2]吴荷宁 综述,彭民 审校.CD4+T、CD8+T淋巴细胞在新型冠状病毒肺炎中的研究进展[J].天津医科大学学报,2021,27(06):658.
[3]王钰铭,于静波,曾强,等.天津市航空口岸新型冠状病毒肺炎疫情输入情况的时空特征分析[J].天津医科大学学报,2023,29(01):63.
WANG Yu-ming,YU Jing-bo,ZENG Qiang,et al.Analysis on spatio-temporal characteristics of imported COVID-19 cases in Tianjin aviation port[J].Journal of Tianjin Medical University,2023,29(02):63.